The wechat account of Yuecang Pharmaceutical YOUCARE said: Recently, Yuecang Pharmaceutical's broad-spectrum coronavirus membrane fusion inhibitor polypeptide (YKYYO17 aerosol inhaler) has been approved by the National Medical Products Administration for clinical trials. YKYY017 atomized inhaler is a Class 1 chemical innovative drug developed by our company with a clear mechanism of action, precise curative effect and complete independent intellectual property rights. This application is for the treatment of novel coronavirus infection.
The clinical approval of the nebulized inhalant is of great significance. Peptide drug inhalation preparation is an innovative high-end preparation, which realizes the efficient utilization of peptide drugs through the inhalation of lung delivery, so that peptide drugs can play a systemic effect, and has a broad application prospect.
YKYY017 aerosol inhaler is the latest generation of broad-spectrum and highly effective coronavirus membrane fusion inhibitor jointly developed by Yuegang Pharmaceutical and Institute of Pathogenic Biology, Chinese Academy of Medical Sciences. It can play an antiviral role by inhibiting membrane fusion pathways on cell surface and endocytic body. Yuegang Pharmaceutical has the global exclusive rights of YKYY017.
At present, the COVID-19 epidemic situation at home and abroad is still severe, and there is an urgent need for effective epidemic prevention and control products. The therapeutic YKYY017 atomizing inhalant is a product with independent intellectual property rights and can be used to treat the novel coronavirus infection, which will help to protect people's life and health.
